Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Innovent Biologics, Inc. and Eli Lilly and Company Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications

12/02/2021 | 11:37pm EST

Innovent Biologics, Inc. and Eli Lilly and Company (Lilly) announced that the innovative PD-1 inhibitor sintilimab has been successfully included in the updated National Reimbursement Drug List ("NRDL") for all approved indications, according to the latest announcement from the China National Healthcare Security Administration ("NHSA"). The updated NRDL will officially take effect on January 1, 2022. A total of four approved indications for sintilimab are now included in the updated NRDL: Three indications for sintilimab have been included in the NRDL for the first time, as follows: in combination with pemetrexed and platinum chemotherapy for the first-line treatment of advanced or recurrent nonsquamous non-small cell lung cancer (nsq NSCLC) without sensitizing EGFR mutations or ALK rearrangements; in combination with gemcitabine and platinum chemotherapy for the first-line treatment of advanced or recurrent squamous non-small cell lung cancer (sq NSCLC); and in combination with BYVASDA? (bevacizumab biosimilar injection) for the first-line treatment of unresectable or advanced hepatocellular carcinoma (HCC). An indication for relapsed or refractory classic Hodgkin's lymphoma (cHL) after two lines or later of systemic chemotherapy, which was first included in the NRDL in 2019, has been successfully renewed this year. Sintilimab, marketed as TYVYT? (sintilimab injection) in China, is an innovative PD-1 inhibitor with global quality standards jointly developed by Innovent and Eli Lilly and Company. Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 /PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab worldwide, to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. In China, sintilimab has been approved and included in the National Reimbursement Drug List (NRDL) for four indications, including: The treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy. In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of nonsquamous non-small cell lung cancer. In combination with gemcitabine and platinum chemotherapy, for the first-line treatment of squamous non-small cell lung cancer. In combination with BYVASDA? (bevacizumab biosimilar injection) for the first-line treatment of unresectable or advanced hepatocellular carcinoma. Additionally, Innovent currently has two regulatory submissions under review in China for sintilimab, for the first-line treatment of esophageal squamous cell carcinoma, and the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma. Additionally, three clinical studies of sintilimab have met their primary endpoints: Phase 2 study as second-line treatment of esophageal squamous cell carcinoma. Phase 3 study as second-line treatment for squamous NSCLC with disease progression following platinum-based chemotherapy. Phase 3 study in combination with BYVASDA? (bevacizumab biosimilar injection) and chemotherapy (pemetrexed and cisplatin) for EGFR-mutated nonsquamous NSCLC following EGFR-TKI treatment In May 2021, the U.S. FDA accepted for review the Biologics License Application (BLA) for sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of nonsquamous non-small cell lung cancer.


ę S&P Capital IQ 2021
All news about ELI LILLY AND COMPANY
12:23pGSK, Vir ramping up U.S. output of COVID antibody drug
RE
10:32aAlzheimer's patient groups protest U.S. Medicare coverage proposal limiting use of new ..
RE
06:42aDZ Bank Upgrades Eli Lilly and Co. to Buy From Hold; Price Target is $291
MT
01/20Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial..
PR
01/19Iterative Scopes, Inc announced that it has received $150 million in funding from Insig..
CI
01/18Evotec, Eli Lilly to Collaborate on Treatments for Metabolic Diseases
MT
01/18Evotec, Eli Lilly to Address Kidney Diseases, Diabetes in Three-Year Drug Discovery Col..
MT
01/18Eli Lilly, Evotec Team Up to Discover Drugs For Metabolic Diseases
MT
01/18Evotec SE Enters into a Drug Discovery Collaboration with Eli Lilly and Company
CI
01/17Abbisko Therapeutics Co., Ltd. Announces Worldwide Collaboration with Eli Lilly and Com..
CI
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 946 M - -
Net income 2021 6 022 M - -
Net Debt 2021 11 909 M - -
P/E ratio 2021 37,8x
Yield 2021 1,37%
Capitalization 220 B 220 B -
EV / Sales 2021 8,31x
EV / Sales 2022 8,19x
Nbr of Employees 35 000
Free-Float -
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 243,13 $
Average target price 284,18 $
Spread / Average Target 16,9%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY-11.98%220 420
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833